文献速递流行病学与生物统计基础与转化研究临床试验与 GCP

妊娠期糖尿病药物治疗对新生儿人体测量学的独立影响:系统综述与荟萃分析

Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2020-05-22

该系统综述与荟萃分析纳入33项随机对照研究(n=4,944),比较二甲双胍、格列本脲与胰岛素治疗妊娠期糖尿病对子代生长的影响。结果显示,在母体血糖控制无差异的情况下,格列本脲暴露新生儿出生体重更重且巨大儿风险增加,二甲双胍暴露新生儿体重更轻且巨大儿风险降低,提示口服降糖药可能通过胎盘对胎儿产生独立作用。

要点

  • 格列本脲暴露新生儿出生体重较胰岛素组重58.20 g,巨大儿风险增加(OR 1.38)。
  • 二甲双胍暴露新生儿出生体重较胰岛素组轻73.92 g,巨大儿风险降低(OR 0.60)。
  • 口服降糖药可跨越胎盘,对胎儿人体测量学的影响可能独立于母体血糖控制。

核心结论

  • 格列本脲暴露新生儿较胰岛素或二甲双胍暴露者更重且脂肪含量倾向增加。
  • 二甲双胍暴露新生儿较胰岛素或格列本脲暴露者更轻且瘦体重减少,独立于母体血糖控制。
  • 口服降糖药可跨越胎盘,对胎儿人体测量学的影响可能源于对胎儿和/或胎盘的直接作用。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Ovid Embase、Medline、Web of Science、ClinicalTrials.gov和Cochrane数据库(建库至2020年2月12日)。
  • 纳入33项随机对照研究(n=4,944),比较二甲双胍、格列本脲或胰岛素治疗妊娠期糖尿病。
  • 22项研究(n=2,801)比较二甲双胍与胰岛素,8项(n=1,722)比较格列本脲与胰岛素,3项(n=421)比较二甲双胍与格列本脲。
  • 排除孕前糖尿病或非糖尿病女性的研究,两名评价者独立评估资格和偏倚风险。

主要发现

  • 11项研究(n=2,204)报告母体结局,空腹血糖、随机血糖或糖化血红蛋白均无差异。
  • 格列本脲暴露新生儿出生体重较胰岛素组重58.20 g(95%CI 10.10-106.31,p=0.02),巨大儿风险增加(OR 1.38,95%CI 1.01-1.89,p=0.04)。
  • 二甲双胍暴露新生儿出生体重较胰岛素组轻73.92 g(95%CI -114.79至-33.06,p<0.001),巨大儿风险降低(OR 0.60,95%CI 0.45-0.79,p<0.001)。
  • 二甲双胍暴露新生儿出生体重较格列本脲组轻191.73 g(95%CI -288.01至-94.74,p<0.001),巨大儿风险降低不显著(OR 0.32,95%CI 0.08-1.19,p=0.09)。
  • 格列本脲暴露新生儿较胰岛素组腹围增加0.90 cm(95%CI 0.03-1.77,p=0.04),胸围增加0.80 cm(95%CI 0.07-1.53,p=0.03)。

关键数值与推荐

  • 格列本脲暴露新生儿出生体重较胰岛素组重58.20 g(95%CI 10.10-106.31,p=0.02)。
  • 格列本脲暴露新生儿巨大儿风险较胰岛素组增加(OR 1.38,95%CI 1.01-1.89,p=0.04)。
  • 二甲双胍暴露新生儿出生体重较胰岛素组轻73.92 g(95%CI -114.79至-33.06,p<0.001)。
  • 二甲双胍暴露新生儿巨大儿风险较胰岛素组降低(OR 0.60,95%CI 0.45-0.79,p<0.001)。
  • 二甲双胍暴露新生儿出生体重较格列本脲组轻191.73 g(95%CI -288.01至-94.74,p<0.001)。

临床怎么用

  • 治疗妊娠期糖尿病选择口服降糖药时,需考虑其对新生儿人体测量学的独立影响。
  • 使用格列本脲者应关注新生儿出生体重增加和巨大儿风险。
  • 使用二甲双胍者应关注新生儿出生体重降低和瘦体重减少。
  • 治疗期间应监测胎儿生长和母体血糖控制。

局限性

  • 纳入研究存在药物剂量异质性。
  • 妊娠期糖尿病诊断标准存在异质性。
  • 报告纵向生长结局的研究较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fetal growth in gestational diabetes mellitus (GDM) is directly linked to maternal glycaemic control; however, this relationship may be altered by oral anti-hyperglycaemic agents. Unlike insulin, such drugs cross the placenta and may thus have independent effects on fetal or placental tissues. We investigated the association between GDM treatment and fetal, neonatal, and childhood growth. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and Cochrane databases were systematically searched (inception to 12 February 2020). Outcomes of GDM-affected pregnancies randomised to treatment with metformin, glyburide, or insulin were included. Studies including preexisting diabetes or nondiabetic women were excluded. Two reviewers independently assessed eligibility and risk of bias, with conflicts resolved by a third reviewer. Maternal outcome measures were glycaemic control, weight gain, and treatment failure. Offspring anthropometric parameters included fetal, neonatal, and childhood weight and body composition data. Thirty-three studies (n = 4,944), from geographical locations including Europe, North Africa, the Middle East, Asia, Australia/New Zealand, and the United States/Latin America, met eligibility criteria. Twenty-two studies (n = 2,801) randomised women to metformin versus insulin, 8 studies (n = 1,722) to glyburide versus insulin, and 3 studies (n = 421) to metformin versus glyburide. Eleven studies (n = 2,204) reported maternal outcomes. No differences in fasting blood glucose (FBS), random blood glucose (RBS), or glycated haemoglobin (HbA1c) were reported. No studies reported fetal growth parameters. Thirty-three studies (n = 4,733) reported birth weight. Glyburide-exposed neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with increased risk of macrosomia (odds ratio [OR] 1.38, 95% CI 1.01-1.89, p = 0.04) versus neonates of insulin-treated mothers. Metformin-exposed neonates were born lighter (-73.92 g, 95% CI -114.79 to -33.06 g, p < 0.001) with reduced risk of macrosomia (OR 0.60, 95% CI 0.45-0.79, p < 0.001) than insulin-exposed neonates. Metformin-exposed neonates were born lighter (-191.73 g, 95% CI -288.01 to -94.74, p < 0.001) with a nonsignificant reduction in macrosomia risk (OR 0.32, 95% CI 0.08-1.19, I2 = 0%, p = 0.09) versus glyburide-exposed neonates. Glyburide-exposed neonates had a nonsignificant increase in total fat mass (103.2 g, 95% CI -3.91 to 210.31, p = 0.06) and increased abdominal (0.90 cm, 95% CI 0.03-1.77, p = 0.04) and chest circumferences (0.80 cm, 95% CI 0.07-1.53, p = 0.03) versus insulin-exposed neonates. Metformin-exposed neonates had decreased ponderal index (-0.13 kg/m3, 95% CI -0.26 to -0.00, p = 0.04) and reduced head (-0.21, 95% CI -0.39 to -0.03, p = 0.03) and chest circumferences (-0.34 cm, 95% CI -0.62 to -0.05, p = 0.02) versus the insulin-treated group. Metformin-exposed neonates had decreased ponderal index (-0.09 kg/m3, 95% CI -0.17 to -0.01, p = 0.03) versus glyburide-exposed neonates. Study limitations include heterogeneity in dosing, heterogeneity in GDM diagnostic criteria, and few studies reporting longitudinal growth outcomes. CONCLUSIONS: Maternal randomisation to glyburide resulted in heavier neonates with a propensity to increased adiposity versus insulin- or metformin-exposed groups. Metformin-exposed neonates were lighter with reduced lean mass versus insulin- or glyburide-exposed groups, independent of maternal glycaemic control. Oral anti-hyperglycaemics cross the placenta, so effects on fetal anthropometry could result from direct actions on the fetus and/or placenta. We highlight a need for further studies examining the effects of intrauterine exposure to antidiabetic agents on longitudinal growth, and the importance of monitoring fetal growth and maternal glycaemic control when treating GDM. This review protocol was registered with PROSPERO (CRD42019134664/CRD42018117503).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Tarry-Adkins JL, Aiken CE, Ozanne SE, et al. Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis. PLoS Med. 2020. PMID: 32442232. doi:10.1371/journal.pmed.1003126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。